| Identification | More | [Name]
Risedronic acid | [CAS]
105462-24-6 | [Synonyms]
(1-HYDROXY-1-PHOSPHONO-2-PYRIDIN-3-YL-ETHYL)PHOSPHONIC ACID
RESEDRONIC ACID
RISEDRONATE
RISEDRONIC ACID
RISEDRONIC ACID MONOHYDRATE
1-Hydroxy-2-(3-pyridyl)-ethan-1,1-bis-phosphonic acid
RISEDRONIC ACID: RISEDRONIC ACID MONOHYDRATE
1-Hydroxy-2-(3-pyridinyl)ethylidenebisphosphonicacidmonohydrate
1-HYDROXY-2-(3-PYRIDINYL)ETHYLIDENE]BISPHOSPHONIC ACID
3-(Acetic acid)Pyridine | [EINECS(EC#)]
600-654-2 | [Molecular Formula]
C7H11NO7P2 | [MDL Number]
MFCD00867080 | [Molecular Weight]
283.11 | [MOL File]
105462-24-6.mol |
| Hazard Information | Back Directory | [Uses]
Risedronic acid is a potentially useful biophosphonate for bone resorption analysis.
| [Uses]
Risedronic Acid is a pyridinyl biphosphonate bone resorption inhibitor. | [Definition]
ChEBI: Risedronic acid is a member of pyridines. It is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone. | [in vivo]
Risedronic acid (Risedronate) (30 μg/kg; subcutaneous injection; once every other day; 3 weeks) prevents radiation-induced osteoporosis in female C57BL/6 mice irradiated with 2 Gy X-rays, inhibits trabecular bone loss and microstructural damage, and suppresses the increase in osteoclast number and serum TRAP5b2.
Risedronic acid (10-25 mg/kg; intraperitoneal injection; once a day; 7 days) inhibits parasitemia in BALB/c mice infected with?Plasmodium berghei?strain ANKA, but does not prolong the survival time of mice3. | Animal Model: | Female C57BL/6 mice (20-week-old, ~23 g) irradiated with 2 Gy X-rays whole-body2 | | Dosage: | 30 μg/kg | | Administration: | Subcutaneous injection, once every other day, for 3 weeks | | Result: | Prevented the radiation-induced increase in osteoclast number, surface, and TRAP5b. |
| Animal Model: | Male BALB/c mice (3-4 weeks old) infected with?Plasmodium berghei?strain ANKA by intraperitoneal injection of?1×106?blood-stage parasites3 | | Dosage: | 10 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg | | Administration: | Intraperitoneal injection, once a day, for 7 days | | Result: | Led to an 88.9% inhibition of the rodent parasite Plasmodium berghei in mice on the seventh day of treatment. |
| [storage]
Store at -20°C | [Mode of action]
Risedronatic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase. Inhibition of osteoclasts results in decreased bone resorption. |
|
|